vs
EXACT SCIENCES CORP（EXAS）与因美纳（ILMN）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是EXACT SCIENCES CORP的1.3倍（$1.2B vs $878.4M），因美纳净利率更高（28.8% vs -9.8%，领先38.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 5.0%），因美纳自由现金流更多（$267.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.7%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
EXAS vs ILMN — 直观对比
营收规模更大
ILMN
是对方的1.3倍
$878.4M
营收增速更快
EXAS
高出18.1%
5.0%
净利率更高
ILMN
高出38.6%
-9.8%
自由现金流更多
ILMN
多$146.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $334.0M |
| 毛利率 | 70.1% | 65.5% |
| 营业利润率 | -9.4% | 17.4% |
| 净利率 | -9.8% | 28.8% |
| 营收同比 | 23.1% | 5.0% |
| 净利润同比 | 90.1% | 185.5% |
| 每股收益（稀释后） | $-0.45 | $2.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASILMN
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | — | ||
| Q2 25 | $811.1M | — | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | $1.1B | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $1.1B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASILMN
| Q4 25 | $-86.0M | $334.0M | ||
| Q3 25 | $-19.6M | — | ||
| Q2 25 | $-1.2M | — | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | $186.0M | ||
| Q3 24 | $-38.2M | $705.0M | ||
| Q2 24 | $-15.8M | $-2.0B | ||
| Q1 24 | $-110.2M | $-126.0M |
毛利率EXASILMN
| Q4 25 | 70.1% | 65.5% | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | 65.9% | ||
| Q3 24 | 69.4% | 69.0% | ||
| Q2 24 | 69.8% | 64.8% | ||
| Q1 24 | 70.0% | 62.0% |
营业利润率EXASILMN
| Q4 25 | -9.4% | 17.4% | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | 15.8% | ||
| Q3 24 | -5.6% | 68.6% | ||
| Q2 24 | -3.8% | -147.2% | ||
| Q1 24 | -16.7% | -10.3% |
净利率EXASILMN
| Q4 25 | -9.8% | 28.8% | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | -0.1% | — | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | 16.8% | ||
| Q3 24 | -5.4% | 65.3% | ||
| Q2 24 | -2.3% | -178.8% | ||
| Q1 24 | -17.3% | -11.7% |
每股收益（稀释后）EXASILMN
| Q4 25 | $-0.45 | $2.16 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | $1.16 | ||
| Q3 24 | $-0.21 | $4.42 | ||
| Q2 24 | $-0.09 | $-12.48 | ||
| Q1 24 | $-0.60 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.7B |
| 总资产 | $5.9B | $6.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASILMN
| Q4 25 | $964.7M | $1.6B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $93.0M | ||
| Q3 24 | $1.0B | $70.0M | ||
| Q2 24 | $946.8M | $74.0M | ||
| Q1 24 | $652.1M | — |
股东权益EXASILMN
| Q4 25 | $2.4B | $2.7B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | $2.4B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.2B | $1.4B | ||
| Q1 24 | $3.1B | $5.7B |
总资产EXASILMN
| Q4 25 | $5.9B | $6.6B | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | $6.3B | ||
| Q3 24 | $6.7B | $6.0B | ||
| Q2 24 | $6.7B | $6.1B | ||
| Q1 24 | $6.4B | $10.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $321.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $267.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 23.0% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.96× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $935.0M |
8季度趋势，按日历期对齐
经营现金流EXASILMN
| Q4 25 | $151.7M | $321.0M | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | $364.0M | ||
| Q3 24 | $138.7M | $316.0M | ||
| Q2 24 | $107.1M | $80.0M | ||
| Q1 24 | $-82.3M | $77.0M |
自由现金流EXASILMN
| Q4 25 | $120.4M | $267.0M | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | $335.0M | ||
| Q3 24 | $112.6M | $284.0M | ||
| Q2 24 | $71.2M | $49.0M | ||
| Q1 24 | $-120.0M | $41.0M |
自由现金流率EXASILMN
| Q4 25 | 13.7% | 23.0% | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | 30.3% | ||
| Q3 24 | 15.9% | 26.3% | ||
| Q2 24 | 10.2% | 4.4% | ||
| Q1 24 | -18.8% | 3.8% |
资本支出强度EXASILMN
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | 2.6% | ||
| Q3 24 | 3.7% | 3.0% | ||
| Q2 24 | 5.1% | 2.8% | ||
| Q1 24 | 5.9% | 3.3% |
现金转化率EXASILMN
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
ILMN
| Product revenue | $990.0M | 85% |
| Service and other revenue | $169.0M | 15% |
